Sumitomo Dainippon Pharma chooses SciFinder from CAS to Enhance Research Productivity and Accelerate Growth

With more pressure than ever on pharmaceutical companies to deliver profitable innovation, solutions from CAS optimize efficiency throughout the R&D pipeline

Columbus, Ohio (July 9, 2018) – CAS, a division of the American Chemical Society (ACS), announced today that Sumitomo Dainippon Pharma has signed a 5-year agreement to provide enterprise-wide access to the newest solution in the SciFinder^® family, SciFinderⁿ.  With SciFinderⁿ, scientists can quickly find the most relevant, actionable answers for their scientific inquiries to accelerate their research outcomes. 
“We are confident that SciFinderⁿ will make our scientists more efficient than ever. Being able to obtain necessary information so much faster will increase the speed of our whole R&D process,” said Kazuhiko Takahashi, Ph.D., executive director of technology R&D at Sumitomo Dainippon Pharma. “We have high expectations that SciFinderⁿ will deliver the insight we need to achieve our goals for innovative drug discovery.” 

For many years, SciFinder has empowered pharmaceutical companies across the globe to achieve success and efficiency in their R&D processes. Sumitomo Dainippon Pharma has utilized SciFinder in creating their pipeline and to support product development. SciFinderⁿ will further this success by providing additional content, enhanced workflow features and the most advanced chemistry relevance engine in the industry, enabling their researchers to be exponentially more productive.

“We value our long-term partnership with Sumitomo Dainippon Pharma and appreciate their continued trust in CAS to support their growth and on-going success,” said Craig Stephens, vice president of sales at CAS. “This organization has set aggressive targets for expanding their pipeline and the unique features of SciFinderⁿ are perfectly suited to enable them in achieving these goals.”

About CAS

CAS, a division of the American Chemical Society, is dedicated to the ACS vision of improving people’s lives through the transforming power of chemistry. The CAS team of highly trained scientists finds, collects and organizes all publicly disclosed substance information, creating the world’s most valuable collection of content that is vital to innovation worldwide. Scientific researchers, patent professionals and business leaders around the world rely on a suite of research solutions from CAS that enables discovery today to fuel tomorrow’s innovation.

About SciFinderⁿ

SciFinderⁿ, the newest solution in the SciFinder family, accelerates scientific research with a frictionless interface to the unmatched CAS content collection and the most advanced chemistry relevance engine in the industry, allowing scientists to do better research in less time.  

About Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma’s goal is to create innovative pharmaceutical products. Psychiatry and neurology, as well as oncology, are our focus therapeutic areas representing significant unmet medical needs. We are also channeling our R&D energies into regenerative medicine/cell therapy. For more details, please visit the Sumitomo Dainippon Pharma website (https://www.ds-pharma.com).

CAS Media Contact:
Tina Tomeo
614-447-3600
cas-pr@cas.org